Vol. 23/No. 5 | OncologyLive

ESR1 Data Fuel Novel Breast Cancer Strategies

March 15, 2022

Mutations on the ESR1 gene, which encodes the estrogen receptor, have emerged as an important driver of resistance to endocrine therapies, which form the backbone of treatment for patients with ER-positive, HER2-negative breast cancer.

HER2 Expression Drives Treatment Decisions in Gastric/Esophageal Cancers

March 14, 2022

Experts in the field of upper gastrointestinal cancers discuss recent data from the European Society for Medical Oncology Congress 2021 that may bolster the uptake of HER2 as a guide for treatment decisions in the second line.

Investigators Look to Enhance Outcomes for Unresectable ESCC With Chemoradiation Combination

March 10, 2022

Since most diagnoses of esophageal squamous cell carcinoma are made when the disease is in advanced stages, investigators have initiated studies to evaluate the efficacy of immunotherapy in earlier lines of therapy, including in combination with chemoradiotherapy.

Ultra-Rare Sarcoma Subgroup Sees First Treatment Option

March 07, 2022

Nab-sirolimus became a treatment option for a rare, aggressive soft-tissue sarcoma—malignant perivascular epithelioid cell tumor—following encouraging data in the first prospective clinical trial for this patient population.